AERSALE CORP (ASLE)

US00810F1066 - Common Stock

7.1  -0.03 (-0.42%)

After market: 7.1 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ASLE. ASLE was compared to 63 industry peers in the Aerospace & Defense industry. While ASLE seems to be doing ok healthwise, there are quite some concerns on its profitability. ASLE has a valuation in line with the averages, but it does not seem to be growing.



2

1. Profitability

1.1 Basic Checks

ASLE had positive earnings in the past year.
In the past year ASLE has reported a negative cash flow from operations.
ASLE had positive earnings in 4 of the past 5 years.
In the past 5 years ASLE reported 4 times negative operating cash flow.

1.2 Ratios

ASLE has a Return On Assets (-1.01%) which is comparable to the rest of the industry.
ASLE has a Return On Equity (-1.25%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -1.01%
ROE -1.25%
ROIC N/A
ROA(3y)4.89%
ROA(5y)3.48%
ROE(3y)5.81%
ROE(5y)4.08%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 27.62%, ASLE is doing good in the industry, outperforming 71.43% of the companies in the same industry.
ASLE's Gross Margin has improved in the last couple of years.
ASLE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.01%
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

ASLE does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASLE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ASLE has more shares outstanding
ASLE has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.39 indicates that ASLE is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.39, ASLE is doing good in the industry, outperforming 61.90% of the companies in the same industry.
ASLE has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ASLE (0.08) is better than 84.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 3.39
ROIC/WACCN/A
WACC9.18%

2.3 Liquidity

ASLE has a Current Ratio of 5.79. This indicates that ASLE is financially healthy and has no problem in meeting its short term obligations.
ASLE's Current ratio of 5.79 is amongst the best of the industry. ASLE outperforms 98.41% of its industry peers.
A Quick Ratio of 1.90 indicates that ASLE should not have too much problems paying its short term obligations.
The Quick ratio of ASLE (1.90) is better than 76.19% of its industry peers.
Industry RankSector Rank
Current Ratio 5.79
Quick Ratio 1.9

3

3. Growth

3.1 Past

ASLE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.02%.
Looking at the last year, ASLE shows a very negative growth in Revenue. The Revenue has decreased by -18.11% in the last year.
ASLE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.99% yearly.
EPS 1Y (TTM)-94.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-108.7%
Revenue 1Y (TTM)-18.11%
Revenue growth 3Y16.99%
Revenue growth 5YN/A
Revenue growth Q2Q-0.71%

3.2 Future

The Earnings Per Share is expected to grow by 252.62% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 3.99% on average over the next years.
EPS Next Y662.57%
EPS Next 2Y252.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.8%
Revenue Next 2Y3.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

4

4. Valuation

4.1 Price/Earnings Ratio

ASLE is valuated quite expensively with a Price/Earnings ratio of 101.43.
ASLE's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 24.55, ASLE is valued quite expensively.
The Price/Forward Earnings ratio is 13.30, which indicates a correct valuation of ASLE.
Based on the Price/Forward Earnings ratio, ASLE is valued cheaply inside the industry as 96.83% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 20.92. ASLE is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 101.43
Fwd PE 13.3

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ASLE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ASLE's earnings are expected to grow with 252.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.15
PEG (5Y)N/A
EPS Next 2Y252.62%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ASLE!.
Industry RankSector Rank
Dividend Yield N/A

AERSALE CORP

NASDAQ:ASLE (5/1/2024, 7:00:01 PM)

After market: 7.1 0 (0%)

7.1

-0.03 (-0.42%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap369.13M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 101.43
Fwd PE 13.3
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.15
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.01%
ROE -1.25%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 27.62%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.79
Quick Ratio 1.9
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-94.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y662.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-18.11%
Revenue growth 3Y16.99%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y